Clinical Trials · NCT02453711
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 957
- Start date
- Oct 2015
- Locations
- 74 sites, 8 countries
- Primary endpoint
- Relative Change in Body Weight (%)